| 1 |
32365274 | The role of the poor metabolizer genotype CYP2D6 and CYP1A2 phenotype in the pharmacokinetics of duloxetine and venlafaxine-A case report. | 2020 Oct |
1 |
| 2 |
30192450 | Differences in Duloxetine Dosing Strategies in Smoking and Nonsmoking Patients: Therapeutic Drug Monitoring Uncovers the Impact on Drug Metabolism. | 2018 Sep 4 |
1 |
| 3 |
27437087 | Inhibition of Cytochrome P450 by Propolis in Human Liver Microsomes. | 2016 Jul |
1 |
| 4 |
21366359 | Duloxetine: clinical pharmacokinetics and drug interactions. | 2011 May |
3 |
| 5 |
21839818 | Reversible time-dependent inhibition of cytochrome P450 enzymes by duloxetine and inertness of its thiophene ring towards bioactivation. | 2011 Oct 30 |
1 |
| 6 |
21979923 | Augmentative effects of fluvoxamine on duloxetine plasma levels in depressed patients. | 2011 Nov |
3 |
| 7 |
19480470 | Duloxetine: a review of its use in the treatment of generalized anxiety disorder. | 2009 |
1 |
| 8 |
19608694 | In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran. | 2009 Oct |
1 |
| 9 |
18307373 | In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. | 2008 |
8 |
| 10 |
17121211 | Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects. | 2006 Oct |
1 |
| 11 |
16400743 | Duloxetine: new drug. For stress urinary incontinence: too much risk, too little benefit. | 2005 Dec |
1 |
| 12 |
19803876 | Duloxetine in the treatment of stress urinary incontinence. | 2005 Nov |
2 |
| 13 |
15057659 | Metabolism of the newest antidepressants: comparisons with related predecessors. | 2004 Feb |
1 |